Abstract:Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by isolated thrombocytopenia caused by increased platelet destruction and impaired platelet production. First-line therapies include corticosteroids, intravenous immunoglobulin, and anti-D immunoglobulin. For patients who are refractory to these therapies, those who become corticosteroid dependent, or relapse following treatment with corticosteroid, options include splenectomy, rituximab, and thrombopoietin-receptor agonists, alongside a variety of additional immunosuppressive and experimental therapies. Despite recent advances in the management of ITP, many areas need further research. Although it is recognized that an assessment of patient-reported outcomes in ITP is valuable to understand and guide treatment, these measures are not routinely measured in the clinical setting. Consequently, although corticosteroids are first-line therapies for both children and adults, there are no data to suggest that corticosteroids improve health-related quality of life or other patient-related outcomes in either children or adults. In fact, long courses of corticosteroids, in either children or adults, may have a negative impact on a patient’s health-related quality of life, secondary to the impact on sleep disturbance, weight gain, and mental health. In adults, additional therapies may be needed to treat overt hemorrhage, but unfortunately the results are transient for the majority of patients. Therefore, there is a need to recognize the limitations of current existing therapies and evaluate new approaches, such as individualized treatment based on the probability of response and the size of effect on the patient’s most bothersome symptoms and risk of adverse effects or complications. Finally, a validated screening tool that identifies clinically significant patient-reported outcomes in routine clinical practice would help both patients and physicians to effectively follow a patient’s health beyond simply treating the laboratory findings and physical symptoms of ITP. The goal of this narrative review is to discuss management of newly diagnosed and refractory patients with ITP, with a focus on the limitations of current therapies from the patient’s perspective.

[Differential diagnosis and therapy of immune thrombocytopenia]

Contemporary management of primary immune thrombocytopenia in adults

Novel treatments for immune thrombocytopenia: targeting platelet autoantibodies

Investigational drugs for immune thrombocytopenia

Advances in the pathophysiology of primary immune thrombocytopenia

Immune thrombocytopenic purpura

Immune Thrombocytopenia (ITP): Current Limitations in Patient Management

Current treatment options for primary immune thrombocytopenia

Current Management of Primary Immune Thrombocytopenia

ITP in the 21st Century

How we treat primary immune thrombocytopenia in adults

The Challenge for a Correct Diagnosis of Refractory Thrombocytopenia: ITP or MDS with Isolated Thrombocytopenia?

Management of children and adolescents with primary immune thrombocytopenia: controversies and solutions

Treatments for Primary Immune Thrombocytopenia: A Review

Novel Therapies to Address Unmet Needs in ITP

Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management

Novel therapies for immune thrombocytopenia

Emerging role of stem cell memory-like T cell (TSCM) in immune thrombocytopenia.

ITP: a historical perspective

Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition

Efgartigimod alfa for the treatment of primary immune thrombocytopenia